Insilico Medicine Slashes Drug Discovery Timelines Using AI in China

The Hong Kong-listed company utilizes AI to pinpoint biological targets and design molecular structures, narrowing the field to a handful of compounds for physical testing. While its fastest program reached candidate nomination in nine months, the process remains anchored in traditional experimental validation. Researchers in Shanghai oversee biological screening and scale-up, leveraging China’s lower operating costs and streamlined regulatory environment to gain a competitive edge over Western incumbents.

Despite the technical efficiency, the commercial reality remains complex. While Insilico has secured 13 investigational new drug clearances and moved its Rentosertib treatment for pulmonary fibrosis into Phase III trials, the company generates over 90% of its revenue from Western pharmaceutical partners. This reliance stems from China’s lower reimbursement rates for novel drugs and ongoing geopolitical restrictions on software exports. As the firm automates its workflows, it estimates that approximately 40% of its software-side workforce could eventually be displaced or retrained to manage robotics and AI evaluation systems, signaling a broader evolution in the biotech labor market.